The explosion of demand for GLP-1 medications such as semaglutide and tirzepatide has propelled US medical spas into the center of a fast-changing and increasingly risky market.
Once marketed primarily as cosmetic or wellness destinations, medispas are now navigating heightened regulatory oversight, growing liability exposures, and a hardening insurance market.
According to Bobbie Williams (pictured), vice president and healthcare practice leader at Novatae Risk Group, the sector’s complexity lies in its hybrid identity. Medispas typically offer cosmetic and aesthetic treatments that are medical in nature, such as Botox, fillers, and laser treatments, under the supervision of a licensed physician.
“I think the defining factor is that medispas are more of an all-inclusive care option,” Williams said. “Instead of going in for one service, like you would to a chiropractor or a physical therapist, people go to a medispa for multiple reasons. It’s not just aesthetic, not just wellness, and not just primary care, it’s a mix of all those.”
Recent federal and state developments have shifted the ground under medispas. The US Food and Drug Administration (FDA) declared GLP-1 drug shortages resolved earlier this year, curtailing allowances for compounding semaglutide and tirzepatide.
States have quickly followed with new restrictions and enforcement actions. Rhode Island passed a law requiring medispas to be licensed facilities with medical directors, while Texas adopted new disclosure rules and tighter oversight of elective IV therapy.
Ohio’s attorney general has issued warning letters to spas marketing compounded weight-loss drugs with misleading claims. Meanwhile, Mississippi has banned off-label use of any drug for weight loss unless it carries an FDA indication.
Williams said these changes are reshaping underwriting decisions. “The main risk (in compounding) is making sure the correct ingredients are used, and dosages are measured properly,” she said.
“The FDA had allowed compounded medications for weight loss treatments, like Wegovy and Ozempic, when brand-name supply was low. Pharmacies were compounding their own versions to fill the gap. But the FDA has tightened its position, and that’s why states are changing their laws.”
The regulatory pressure has translated into a tougher environment for coverage. Williams confirmed that the medispa market is hardening, with underwriters requiring stricter compliance checks before binding policies.
Beyond liability, insurers are scrutinizing operational safeguards. Consent forms, patient education materials, staff licensing, and in-person supervision are all prerequisites for favorable terms.
Mail-order prescriptions, such as Ozempic by mail, are also becoming popular, but bring more exposure to providers. “(Underwriters) want patients seen in person by a qualified provider who can evaluate whether the medication is appropriate as part of a broader plan, including diet and exercise,” said Williams.
Professional liability remains the cornerstone of coverage, but exposures vary widely depending on the services offered. Minor missteps in microneedling or facials can trigger claims, while fat transfer or injectable weight-loss programs carry far higher stakes.
“It could be as simple as using the wrong needle, or as complex as dosage errors with compounded peptides,” Williams said.
Ultimately, Williams believes carrier actions will help reinforce regulatory compliance.
“Our policies already exclude non-FDA approved drugs, but we carve back coverage for certain prescriptions when the right parameters are in place,” she said. “As carriers get more specific, providers will have no choice but to align with FDA rules or lose their coverage.”
That alignment may prove critical for the industry’s long-term legitimacy. Medispas once occupied a regulatory gray zone, but the surge in weight-loss treatments has brought them under the same scrutiny as traditional healthcare providers.
Getting adequate medical professional liability coverage will be critical for these health providers as risks evolve. Miscellaneous professional liability coverage, Williams noted, covers them “if, for example, a treatment is administered incorrectly.”
“Some procedures are more invasive, like liposuction or fat transfer,” she said. “Not technically surgery, but close. In those cases, you have higher exposure. On the lower end, it might be something like using the wrong needle during microneedling.
“And then there’s weight loss treatment. If dosages are wrong or patients aren’t properly qualified, that’s another exposure.”
Williams urged brokers to align with underwriters deeply familiar with the sector. “Often, when a generalist tries to step in and offer coverage for medispas or allied healthcare risks, they may not have the depth of knowledge needed,” she said. “Finding an underwriter who is comfortable and experienced in this sector is key.”
She also stressed the importance of packaging client information thoroughly. Brokers should present evidence of compliance, including copies of consent forms, staff credentialing, oversight protocols, and marketing practices that align with state advertising rules.
“These providers are so skilled and qualified that they want to take on new opportunities to offer treatment,” said Williams. “That's a wonderful thing, but we want to make sure that we're covering them properly.”
